Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.

Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, Modugno F, Jiang W, Grimm M, Basse PH, Bartlett DL, Edwards RP, Kalinski P.

Cancer Res. 2018 Aug 1;78(15):4292-4302. doi: 10.1158/0008-5472.CAN-17-3985. Epub 2018 May 31.

PMID:
29853604
2.

Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.

Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P.

Nat Protoc. 2018 Feb;13(2):335-357. doi: 10.1038/nprot.2017.130. Epub 2018 Jan 18.

PMID:
29345636
3.

Tumor Immuno-Environment in Cancer Progression and Therapy.

Kalinski P, Talmadge JE.

Adv Exp Med Biol. 2017;1036:1-18. doi: 10.1007/978-3-319-67577-0_1.

PMID:
29275461
4.

Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells.

Rodríguez-Ubreva J, Català-Moll F, Obermajer N, Álvarez-Errico D, Ramirez RN, Company C, Vento-Tormo R, Moreno-Bueno G, Edwards RP, Mortazavi A, Kalinski P, Ballestar E.

Cell Rep. 2017 Oct 3;21(1):154-167. doi: 10.1016/j.celrep.2017.09.018.

5.

Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model.

Budiu RA, Vlad AM, Nazario L, Bathula C, Cooper KL, Edmed J, Thaker PH, Urban J, Kalinski P, Lee AV, Elishaev EL, Conrads TP, Flint MS.

Cancer Clin Oncol. 2017 May;6(1):12-24. doi: 10.5539/cco.v6n1p12. Epub 2016 Nov 11.

6.

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL.

Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Review.

7.

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL.

Nat Commun. 2017 Mar 27;8:14754. doi: 10.1038/ncomms14754.

8.

Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues.

Muthuswamy R, Okada NJ, Jenkins FJ, McGuire K, McAuliffe PF, Zeh HJ, Bartlett DL, Wallace C, Watkins S, Henning JD, Bovbjerg DH, Kalinski P.

Brain Behav Immun. 2017 May;62:78-86. doi: 10.1016/j.bbi.2017.02.008. Epub 2017 Feb 16.

PMID:
28212885
9.

Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.

Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P.

Prostate. 2016 Sep;76(12):1095-105. doi: 10.1002/pros.23194. Epub 2016 May 16.

PMID:
27199259
10.

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.

Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL.

Oncoimmunology. 2015 Oct 29;5(3):e1091554. eCollection 2016 Mar.

11.

Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer.

Radomski M, Zeh HJ, Edington HD, Pingpank JF, Butterfield LH, Whiteside TL, Wieckowski E, Bartlett DL, Kalinski P.

J Immunother Cancer. 2016 Apr 19;4:24. doi: 10.1186/s40425-016-0128-y. eCollection 2016.

12.

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.

Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL.

Oncotarget. 2016 Apr 19;7(16):22174-85. doi: 10.18632/oncotarget.7907.

13.

Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.

Wong JL, Obermajer N, Odunsi K, Edwards RP, Kalinski P.

Cancer Immunol Res. 2016 Apr;4(4):303-11. doi: 10.1158/2326-6066.CIR-15-0157. Epub 2016 Jan 27.

14.

Toward improved effectiveness of bladder cancer immunotherapy.

Kalinski P, Gingrich JR.

Immunotherapy. 2015;7(10):1039-42. doi: 10.2217/imt.15.71. Epub 2015 Oct 28. No abstract available.

15.

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.

Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, Lefebvre A, Shugay M, Tong J, Vaudry D, Arkle S, doRego JC, Górecki DC.

PLoS Med. 2015 Oct 13;12(10):e1001888. doi: 10.1371/journal.pmed.1001888. eCollection 2015 Oct.

16.

Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.

Liu J, Li F, Ping Y, Wang L, Chen X, Wang D, Cao L, Zhao S, Li B, Kalinski P, Thorne SH, Zhang B, Zhang Y.

Oncotarget. 2015 Sep 22;6(28):24978-89. doi: 10.18632/oncotarget.4617.

17.

CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.

Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, Zhang B, Kalinski P, Zhang Y.

Br J Cancer. 2015 Sep 1;113(5):747-55. doi: 10.1038/bjc.2015.290. Epub 2015 Aug 18.

18.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

19.

Neurocognitive Impairment as One Facet of Cancer-Related Sickness Behavior Symptoms.

Low CA, Kalinski P, Bovbjerg DH.

J Natl Cancer Inst. 2015 Jun 22;107(8). pii: djv176. doi: 10.1093/jnci/djv176. Print 2015 Aug. No abstract available.

20.

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.

Muthuswamy R, Wang L, Pitteroff J, Gingrich JR, Kalinski P.

J Immunother Cancer. 2015 Mar 24;3:6. doi: 10.1186/s40425-015-0050-8. eCollection 2015.

21.

[Expression and clinical significance of CCL5 in patients with esophageal carcinoma].

Liu J, Li F, Chen X, Wang L, Yue D, Zhao S, Hu W, Kalinski P, Thorne S, Hou J, Zhang Y.

Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):828-33. Chinese.

PMID:
25620479
22.

CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity.

Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB.

J Immunol. 2015 Feb 1;194(3):1047-56. doi: 10.4049/jimmunol.1401832. Epub 2014 Dec 29.

23.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

24.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

25.

Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

Nguyen T, Urban J, Kalinski P.

Immunotargets Ther. 2014 Oct 6;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. Review.

26.

IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients.

Wong JL, Muthuswamy R, Bartlett DL, Kalinski P.

Oncoimmunology. 2013 Sep 1;2(9):e26245. Epub 2013 Sep 12.

27.

Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling.

Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, Odunsi K, Billiar TR, Kalinski P.

J Exp Med. 2013 Jul 1;210(7):1433-445.

28.

IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.

Wong JL, Berk E, Edwards RP, Kalinski P.

Cancer Res. 2013 Aug 1;73(15):4653-62. doi: 10.1158/0008-5472.CAN-12-4366. Epub 2013 Jun 12.

29.

Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.

Kalinski P, Muthuswamy R, Urban J.

Expert Rev Vaccines. 2013 Mar;12(3):285-95. doi: 10.1586/erv.13.22. Review.

PMID:
23496668
30.

Generation of myeloid-derived suppressor cells using prostaglandin E2.

Obermajer N, Kalinski P.

Transplant Res. 2012 Sep 28;1(1):15. doi: 10.1186/2047-1440-1-15.

31.

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.

32.

The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Tang D, Lotze MT, Zeh HJ 3rd.

J Immunol. 2013 Feb 1;190(3):1372-9. doi: 10.4049/jimmunol.1201151. Epub 2012 Dec 26.

33.

Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs.

Berk E, Kalinski P.

Oncoimmunology. 2012 Nov 1;1(8):1443-1444.

34.
35.

PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells.

Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P.

Immunol Invest. 2012;41(6-7):635-57. doi: 10.3109/08820139.2012.695417. Review.

PMID:
23017139
36.

Immunobiology of human mucin 1 in a preclinical ovarian tumor model.

Budiu RA, Elishaev E, Brozick J, Lee M, Edwards RP, Kalinski P, Vlad AM.

Oncogene. 2013 Aug 8;32(32):3664-75. doi: 10.1038/onc.2012.397. Epub 2012 Sep 10.

37.
38.

NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.

Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P.

Cancer Res. 2012 Aug 1;72(15):3735-43. doi: 10.1158/0008-5472.CAN-11-4136. Epub 2012 May 16.

39.

Immunotherapy of cancer in 2012.

Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S.

CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. Review.

40.

Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs.

Berk E, Muthuswamy R, Kalinski P.

Vaccine. 2012 Sep 21;30(43):6216-24. doi: 10.1016/j.vaccine.2012.04.077. Epub 2012 May 1.

41.

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation.

Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K.

Cancer Immunol Immunother. 2012 Nov;61(11):2013-20. doi: 10.1007/s00262-012-1265-x. Epub 2012 Apr 22.

PMID:
22527253
42.

Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine.

Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz AS, Kalinski P, Nakamura H, Chida K.

Vaccine. 2012 Mar 30;30(16):2633-9. doi: 10.1016/j.vaccine.2012.02.026. Epub 2012 Feb 22.

PMID:
22365841
43.

Regulation of immune responses by prostaglandin E2.

Kalinski P.

J Immunol. 2012 Jan 1;188(1):21-8. doi: 10.4049/jimmunol.1101029. Review.

44.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

45.

IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination.

Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, Kalinski P, Khader SA.

Eur J Immunol. 2012 Feb;42(2):364-73. doi: 10.1002/eji.201141569. Epub 2011 Dec 20.

46.

Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA.

Umemura N, Zhu J, Mburu YK, Forero A, Hsieh PN, Muthuswamy R, Kalinski P, Ferris RL, Sarkar SN.

Cancer Res. 2012 Jan 1;72(1):45-55. doi: 10.1158/0008-5472.CAN-11-1484. Epub 2011 Nov 4.

47.

PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P.

Cancer Res. 2011 Dec 15;71(24):7463-70. doi: 10.1158/0008-5472.CAN-11-2449. Epub 2011 Oct 24.

48.

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P.

Blood. 2011 Nov 17;118(20):5498-505. doi: 10.1182/blood-2011-07-365825. Epub 2011 Oct 4.

49.

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL.

Immunol Res. 2011 Aug;50(2-3):235-47. doi: 10.1007/s12026-011-8224-z.

50.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.

Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM.

J Transl Med. 2011 May 12;9:60. doi: 10.1186/1479-5876-9-60.

Supplemental Content

Loading ...
Support Center